New treatment options for chemotherapy-induced nausea and vomiting (Q35825916)

10 August 2017

1 reference

title

New treatment options for chemotherapy-induced nausea and vomiting (English)

1 reference

10 August 2017

Paul J Hesketh

1

1 reference

10 August 2017

publication date

30 June 2004

1 reference

Supportive Care in Cancer

10 August 2017

published in

1 reference

10 August 2017

volume

12

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

550-554

1 reference

Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist

10 August 2017

cites work

1 reference

12 December 2020

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

12 December 2020

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence

1 reference

12 December 2020

Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor

1 reference

12 December 2020

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

12 December 2020

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

Palonosetron (Helsinn).

1 reference

12 December 2020

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

1 reference

12 December 2020

The tachykinin NK1 receptor in the brain: pharmacology and putative functions

1 reference

12 December 2020

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1 reference

12 December 2020

Drug treatment of chemotherapy-induced delayed emesis

1 reference

12 December 2020

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

1 reference

12 December 2020

10.1007/S00520-004-0651-0

Identifiers

DOI

0 references

1 reference